12 Feb Portfolio Company Spotlight: Alleviant Medical (Chronic Heart Failure)
Learn how Alleviant's no-implant approach addresses the full spectrum of chronic heart failure....
19 Dec Year in Review 2024
RiverVest Year in Review: 2024...
12 Dec RiverVest Welcomes John Cambier and Gary DeCrescenzo to Scientific Advisory Board
ST. LOUIS (December 12, 2024)—RiverVest Venture Partners, a leading life science venture capital firm, today announced that John C. Cambier, Ph.D., and Gary De Crescenzo have joined the firm’s Scientific Advisory Board. Composed of leaders in medical research, RiverVest’s Scientific Advisory Board provides expert guidance...
14 Nov Diabetes Treatment: A Story of Complicated Progress and Great Potential
RiverVest speaks with Lyn Baranowski, CEO of portfolio company Avalyn Pharma, about who she is, what brought her to Avalyn, and what fuels her passion for building great companies....
16 Oct RiverVest Venture Partners Welcomes Nafise Masoumi as Senior Associate
OCTOBER 2024RiverVest Venture Partners Welcomes Nafise Masoumi as Senior Associate Nafise Masoumi, PhDST. LOUIS--(October 16, 2024)--Life sciences venture capital firm RiverVest Venture Partners today announced that Nafise Masoumi, Ph.D. has joined the firm as senior associate based in the San Diego office, where she will focus...
05 Sep Meet the Leader: Lyn Baranowski, CEO of Avalyn Pharma
RiverVest speaks with Lyn Baranowski, CEO of portfolio company Avalyn Pharma, about who she is, what brought her to Avalyn, and what fuels her passion for building great companies....
18 Jul RiverVest Venture Partners Promotes Andrew Kleiboeker and Jeff Seitz
JULY 2024RiverVest Venture Partners Announces Promotions ST. LOUIS (July 18, 2024)ST. LOUIS, July 18, 2024– RiverVest Venture Partners today announced the promotions of two members of its team. Andrew Kleiboeker has been promoted to associate, and Jeff Seitz to senior analyst. "Both Andrew and Jeff have shown...
10 Jun Niall O’Donnell, Ph.D. Honored by UC San Diego’s Rady School of Management’s Sullivan Center for Entrepreneurship
June 2024O'Donnell Honored for Entrepreneurial Achievement by UC San Diego's Rady School of Management Niall O'Donnell, Ph.D. RiverVest Managing Director San Diego, CA (June 5, 2024) – UC San Diego’s Rady School of Management named Niall O’Donnell, Ph.D. (Rady MBA Class of 2006) the Sullivan Center for...
26 Feb Global Clinical Trial Investigates Novel Heart Failure Treatment
RiverVest's latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease. ...
13 Dec RiverVest Venture Partners Promotes Karen Spilizewski and Isaac Zike to Managing Director and Pascal Krotee to Principal
DECEMBER 2023RiverVest Venture Partners Promotes Karen Spilizewski and Isaac Zike to Managing Director and Pascal Krotee to Principal ST. LOUIS (December 14, 2023)ST. LOUIS, December 14, 2023 – RiverVest Venture Partners today announced the promotions of three current team members: Karen Spilizewski and Isaac Zike, Ph.D....
03 Nov Pascal Krotee Wins Life Science Catalyst Award
November 2023RiverVest's Pascal Krotee Wins Life Science Catalyst Award Pascal Krotee, Ph.D. RiverVest Senior Associate San Diego, CA (November 1, 2023) – Biocom California today announced the winners of its Eighth Annual Life Science Catalyst Award. RiverVest Senior Associate Pascal Krotee, Ph.D. was among 10 life science...
08 Aug Mitochondrial Challenges: Innovations in Research and Patient-Centered Care
RiverVest's latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease. ...
03 Aug CASE STUDY: GOOD THERAPEUTICS
This is a case study of RiverVest portfolio company Good Therapeutics, which was acquired by Roche in 2022 for $250 million upfront plus potential milestone returns....
13 Jun The Orphan Drug Act of 1983 by Niall O’Donnell
In this article, Managing Director Niall O’Donnell, Ph.D. discusses the law that transformed orphan drug development and how one actor’s starring role in its passage spurred 40 years of prolific, life-saving innovation. ...
24 Apr CASE STUDY: Standard Bariatrics
This is a case study of RiverVest's role in financing and guiding Cincinnati-based portfolio company Standard Bariatrics through acquisition by Teleflex, Inc....
03 Jan IN THE NEWS / RiverVest’s Tom Melzer Forecasts St. Louis VC, Start-up Growth for 2020
JAN 2020RiverVest's Tom Melzer Forecasts St. Louis VC, Start-up Growth for 2020 /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} ST. LOUIS (January 3, 2020) St. Louis Business JournalRead the Press ReleasePerhaps no part of the St. Louis economy surged in the past decade more...